Supplemental Table 3 from Anastrozole Dose Escalation for Optimal Estrogen Suppression in Postmenopausal Early-Stage Breast Cancer: A Prospective Trial
Key Points
Key points are not available for this paper at this time.
Abstract
Supplemental Table 3: Representativeness of Study Participants.
Supplemental Table 3 from Anastrozole Dose Escalation for Optimal Estrogen Suppression in Postmenopausal Early-Stage Breast Cancer: A Prospective Trial | Synapse